Treatment Persistence With Monthly Zoledronic Acid is Associated With Lower Risk and Frequency of Skeletal Complications in Patients With Breast Cancer and Bone Metastasis
Authors:
- Hind T. HatoumHHHind T. Hatoum
- Swu-Jane LinSLSwu-Jane Lin
- Matthew R. SmithMSMatthew R. Smith
- Amy GuoAGAmy Guo
- Allan LiptonALAllan Lipton
- 1 June 2011
- journal article
- Published by Elsevier in Clinical Breast Cancer
- Vol. 11 (3) , 177-183
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast CancerNew England Journal of Medicine, 2009
- Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acidCancer, 2008
- Zoledronic AcidDrugs, 2008
- Zoledronic Acid and Survival in Breast Cancer Patients with Bone Metastases and Elevated Markers of Osteoclast ActivityThe Oncologist, 2007
- Potential Use of Bisphosphonates in the Prevention of Metastases in Early-Stage Breast CancerClinical Breast Cancer, 2007
- Role of Bisphosphonates for the Management of Skeletal Complications and Bone Pain from Skeletal MetastasesSupportive Cancer Therapy, 2006
- Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 2005
- American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast CancerJournal of Clinical Oncology, 2003
- Prognostic significance of the number of bone scan abnormalities at the time of initial bone metastatic recurrence in breast carcinomaCancer, 2001
- Management of Bone MetastasesThe Oncologist, 2000